Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | PTGIR | P43119 | 5/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13635190 | 0.84 | KMT2A (0.35) | KMT2AL3MBTL1KDM1AMAOBKDM4E | |
| SCHEMBL13635243 | 0.82 | KMT2A (0.35) | KMT2AL3MBTL1TLR2TLR1KLK7 | |
| SCHEMBL14427327 | 0.79 | KMT2A (0.34) | KMT2AL3MBTL1TLR2TLR1KLK7 | |
| SCHEMBL13635368 | 0.78 | CHRM3 (0.33) | — | |
| SCHEMBL13635193 | 0.78 | CHRM3 (0.33) | — | |
| SCHEMBL13635367 | 0.77 | KDM4C (0.35) | KMT2A | |
| SCHEMBL14281455 | 0.77 | KMT2A (0.34) | KMT2AL3MBTL1TLR2TLR1KLK7 | |
| SCHEMBL13767392 | 0.76 | CHRM3 (0.36) | — | |
| SCHEMBL13864820 | 0.75 | BTK (0.33) | KMT2AALOX5APFEN1 | |
| SCHEMBL15195059 | 0.74 | PTGIR (0.60) | KMT2AL3MBTL1KLK7PTGIRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197612-A1 | 2-{-3-'2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197612-A1 | 2-{-3-'2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | PPARA, PPARG, PPARD | KMT2A 2098/4885L3MBTL1 2755/4885TLR2 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.